Zentalis
Zentalis :
Discovering and developing best-in-class small molecule therapeutics targeting fundamental biological cancer pathways. Pipeline includes ZN-c3, a WEE1 inhibitor for advanced solid tumors (currently enrolling a Ph 2 Fast Track trial in USC and planning to initiate a potentially registrational biomarker-driven trial), ZN-c5, an oral SERD for breast cancer, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for NSCLC. Multiple mono and combo trials are ongoing/planned across pipeline.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Market Cap
1B +
Website:
Profiles:
Address:
530 Seventh Avenue, Ste 2201
Corner of 39 St
New York, NY 10018
United States
Corner of 39 St
New York, NY 10018
United States
More info:
My account:
Company Participants at Zentalis R&D Day
- Anthony Sun, CEO
Lead Programs
ZN-c5: Oral SERD
oral selective estrogen receptor degrader (SERD)
| Indication | Phase |
|---|---|
| Breast Cancer | 1/2 |
ZN-c3: WEE1
oral inhibitor of WEE1
| Indication | Phase |
|---|---|
| Solid Tumors | 1/2 |
ZN-d5: BCL-2
oral selective inhibitor of B-cell lymphoma 2 (BCL-2)
| Indication | Phase |
|---|---|
| Hematologic Malignancies | IND |
ZN-e4: EGFR
oral, small molecule inhibitor of mutant epidermal growth factor receptor (EGFR)
| Indication | Phase |
|---|---|
| NSCLC | 1/2 |
Top 10 Holders of Zentalis Pharmaceuticals, Inc.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Fidelity Management & Research Co. LLC | 12.85 | 5,855,415 | 131.22 | 13F | 3/31/22 |
| Matrix Capital Management Co. LP | 9.55 | 4,349,279 | 97.47 | 13F | 3/31/22 |
| T. Rowe Price Associates, Inc. (Investment Management) | 9.21 | 4,198,180 | 94.08 | 13F | 3/31/22 |
| The Vanguard Group, Inc. | 7.03 | 3,186,986 | 71.42 | Stakes | 12/31/21 |
| Avidity Partners Management LP | 6.97 | 3,176,999 | 71.20 | 13F | 3/31/22 |
| Vanguard Group, Inc. (Subfiler) | 6.91 | 3,148,449 | 70.56 | 13F | 3/31/22 |
| Tybourne Capital Management (HK) Ltd. | 5.32 | 2,426,095 | 54.37 | 13F | 3/31/22 |
| State Street Corp. | 4.57 | 2,080,440 | 46.62 | 13F | 3/31/22 |
| Viking Global Investors LP | 4.45 | 2,026,656 | 45.42 | 13F | 3/31/22 |
| BlackRock Fund Advisors | 3.33 | 1,516,533 | 33.99 | 13F | 3/31/22 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.